We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Fascia Iliaca Compartment Block For Analgesia After Total Hip Arthroplasty (FICB)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01758497
First Posted: January 1, 2013
Last Update Posted: December 29, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
St. Luke's-Roosevelt Hospital Center
  Purpose

Introduction Fascia Iliaca compartment block (FICB) is commonly used to treat pain in patients after total hip arthroplasty (THA) despite the lack of RCTs to evaluate the efficacy of FICB for this indication. Therefore the objective of this study was to assess the analgesic benefit of FICB for post-operative pain management in THA.

Methods After IRB approval and informed consent, patients having THA at our center in the period 2010-2011 were recruited. Eligible patients were adults, ASA physical status I-III, and BMI <30) with no contraindication to study procedures. In the PACU, all patients received morphine sulfate IVPCA; patients reporting pain > 3 on the NRS-11 despite IVPCA were randomized by the method of sealed envelopes to receive US guided injections of 30ml 0.5% ropivacaine (FICB) or 30ml 0.9% NaCl (sham block, SB) beneath the fascia iliaca.

The primary outcome variable was opioid analgesic consumption during the first 24 h postoperatively. Secondary outcome measures were pain intensity (NRS-11) and extent of sensory blockade.


Condition Intervention
Pain Disorder Sensory Deficit Procedure: Fascia iliaca compartment block Procedure: Fascia Iliaca compartment block

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Fascia Iliaca Compartment Block For Analgesia After Total Hip Arthroplasty; A Randomized Double Blind, Placebo-Controlled Trial

Further study details as provided by St. Luke's-Roosevelt Hospital Center:

Primary Outcome Measures:
  • Opioid analgesic consumption [ Time Frame: 24 h postoperatively ]

Secondary Outcome Measures:
  • Pain intensity (NRS-11) and extent of sensory blockade [ Time Frame: 24 h postoperatively ]
    Pain intensity was assessed immediately before and after block placement and at 10-min intervals for the first 30 min after block. Sensory assessment was at 30 min after block, using a pinprick test in the lateral, medial and anterior aspects of the thigh. Specifically, sensation in the territories of the lateral femoral cutaneous, obturator, and femoral nerves was tested using a scale of 0-2 ( 0 = no sensation, 1 = diminished sensation, 2= full sensation). Assessment of motor blockade was not possible because of lower extremity immobilization after surgery to prevent hip dislocation.


Enrollment: 32
Study Start Date: October 2010
Study Completion Date: August 2011
Primary Completion Date: August 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Ropivacaine
US guided injections of 30 ml 0.5% ropivacaine (Fascia Iliaca Compartment Block)
Procedure: Fascia iliaca compartment block
30 ml 0.5% ropivacaine, beneath the fascia iliaca
Other Names:
  • Ultrasound guided Fascia iliaca compartment block
  • FICB
Sham Comparator: Saline
US guided injections of 30 ml 0.9% NaCl (Fascia Iliaca Compartment Block)
Procedure: Fascia Iliaca compartment block
30 ml 0.9% NaCl (sham block, SB), beneath the fascia iliaca
Other Names:
  • Ultrasound guided Fascia iliaca compartment block
  • FICB

Detailed Description:

Introduction Fascia Iliaca compartment block (FICB) is commonly used to treat pain in patients after total hip arthroplasty (THA) despite the lack of RCTs to evaluate the efficacy of FICB for this indication. Therefore the objective of this randomized, prospective trial was to assess the analgesic benefit of FICB for post-operative pain management in THA. Our hypothesis was that FICB would confer an analgesic benefit for patients after THA.

Methods After IRB approval and informed consent, patients having THA at our center in the period 2010-2011 were recruited in the morning of their surgery. Eligible patients were adults, ASA physical status I-III, and BMI <30) with no contraindication to study procedures. In the PACU, all patients received morphine sulfate IVPCA; patients reporting pain > 3 on the NRS-11 despite IVPCA were randomized by the method of sealed envelopes to receive US guided injections of 30ml 0.5% ropivacaine (FICB) or 30ml 0.9% NaCl (sham block, SB) beneath the fascia iliaca.

The primary outcome variable was opioid analgesic consumption during the first 24 h postoperatively. Secondary outcome measures were pain intensity (NRS-11) and extent of sensory blockade.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Adults
  • ASA physical status I-III
  • BMI<30
  • No contraindications to study procedures

Exclusion Criteria:

  • Pediatric patients
  • ASA physical status IV
  • BMI>30
  • Contraindications to study procedures
  • Hypersensitivity to local anesthetics
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01758497


Locations
United States, New York
St Luke's Roosevelt Hospitals
New York, New York, United States, 10025
Sponsors and Collaborators
St. Luke's-Roosevelt Hospital Center
Investigators
Study Director: Admir Hadzic, MD,PhD St. Luke's-Roosevelt Hospital Center
  More Information

Publications:

Responsible Party: St. Luke's-Roosevelt Hospital Center
ClinicalTrials.gov Identifier: NCT01758497     History of Changes
Other Study ID Numbers: 09-042
First Submitted: June 6, 2012
First Posted: January 1, 2013
Last Update Posted: December 29, 2016
Last Verified: December 2016

Keywords provided by St. Luke's-Roosevelt Hospital Center:
Fascia Iliaca compartment block, Pain, Sensorial blockade

Additional relevant MeSH terms:
Somatoform Disorders
Mental Disorders
Ropivacaine
Anesthetics, Local
Anesthetics
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents